Decision Makers
| Name (plus bio) |
Position |
| Dr. Leslie Hudson |
President, Chief Executive Officer and Director |
| Gil Price |
CEO and Chief Medical Officer, Drug Safety Solutions |
| John C. Hodgman |
President and Chief Executive Officer, Cygnus, Inc. |
| John W. Fara |
President and Chief Executive Officer, Depomed Inc. |
| J. David Boyle |
Senior Vice President Finance and Cfo |
| J. David Boyle II |
Senior Vice President Finance and CFO |
| J. David Boyle II |
Senior Vice President Finance and CFO |
| Mark M. Webber |
Cfo |
| Paul Medeiros |
Senior Vice President of Business Development, Chief Business Officer |
| Stephen B. Shrewsbury |
Chief Medical Officer and Senior Vice President of Clinical and Regulatory Affairs |
| Dwight D. Weller |
Senior Vice President of Chemistry and Manufacturing |
| Patrick Iversen |
Senior Vice President of Research and Development |
| Peter D. O'Hanley |
Senior Vice President |
| Ryszard Kole |
Senior Vice President of Discovery Research |
| Janet Rose Rea |
Vice President of Regulatory Affairs and Quality |
| Jody Cain |
Vice President, Lippert, Heilshorn & Associates |
| Joseph B. Horn |
Vice President, Cardiology |
| R. Ray Cummings |
Vice President of Business Development |
| Ray Cummings |
Vice President, Business Development |
| Shirley J Leow |
Vice President of Clinical Operations and Project Management |
| Bruce Voss |
Managing Director, Lippert, Heilshorn & Associates |
| K. Michael Forrest |
Outside Director |
| Kathleen Behrens |
Director of Avi |
| Michael Hubbard |
Director of Investor Relations, Avi Biopharma, Inc. |
| Sidney Altman |
Postdoctoral Fellow In the Laboratory of Dr. |
| Alan P. Timmins |
Director |
Board of Directors
| Organization |
Position |
Status |
| AVI BioPharma, Inc. |
CEO and Chief Medical Officer, Drug Safety Solutions |
Current |
| Drug Safety Solutions |
CEO and Chief Medical Officer |
Current |
| Drug Safety Solutions |
Chief Medical Officer |
Current |
| Global Drug Development Experts, LLC |
Clinical Physician |
Current |
| AVI BioPharma, Inc. |
Board of Directors |
Current |
| Organization |
Position |
Status |
| AVI BioPharma, Inc. |
President and Chief Executive Officer, Cygnus, Inc. |
Current |
| InterMune, Inc. |
Senior Vice President and Chief Financial Officer |
Current |
| AVI BioPharma, Inc. |
Chairman |
Current |
| Inflazyme Pharmaceuticals Ltd |
Board of Directors |
Current |
| Alpha Innotech Corporation |
Board of Directors |
Current |
| AeroGen, Inc. |
Board of Directors |
Current |
| Immersion Corporation |
Board of Directors |
Current |
| Cygnus, Inc. |
CEO |
Former |
| AeroGen, Inc. |
Chief Executive Officer |
Former |
| AeroGen, Inc. |
President |
Former |
| Cygnus, Inc. |
President |
Former |
| Cygnus, Inc. |
Chief Financial Officer |
Former |
| Cygnus, Inc. |
Vice President of Finance |
Former |
| Central Point Software |
Officer |
Former |
| Cygnus, Inc. |
Chairman |
Former |
| Immersion Corporation |
Chairman |
Former |
| University of Utah |
M.B.A. |
Former |
| Brigham Young University |
bachelor's degree |
Former |
| University of Utah |
B.S. |
Former |
| Brigham Young University |
bachelor's degree |
Former |
| Organization |
Position |
Status |
| AVI BioPharma, Inc. |
President and Chief Executive Officer, Depomed Inc. |
Current |
| IOMED, Inc. |
Board of Directors |
Current |
| Depomed, Inc. |
Board of Directors |
Current |
| AVI BioPharma, Inc. |
Board of Directors |
Current |
| Depomed, Inc. |
Chief Executive Officer |
Former |
| Anergen |
Chief Executive Officer |
Former |
| Prototek Corporation |
President |
Former |
| Anergen |
President |
Former |
| Depomed, Inc. |
President |
Former |
| Prototek Corporation |
Vice President of Business Development |
Former |
| AVI BioPharma, Inc. |
Director of Avi |
Former |
| Prototek Corporation |
Director of Biomedical Research |
Former |
| Depomed, Inc. |
Chairman |
Former |
| University of California, Los Angeles |
Ph.D. |
Former |
| University of Wisconsin |
B.S. |
Former |
| Organization |
Position |
Status |
| XOMA Corporation |
CFO & Vice President, Finance |
Current |
| AVI BioPharma, Inc. |
Senior Vice President Finance and Cfo |
Current |
| Salix Pharmaceuticals, Inc. |
Chief Financial Officer |
Former |
| Polycom, Inc. |
Chief Financial Officer |
Former |
| Salix Pharmaceuticals, Inc. |
Executive Vice President |
Former |
| Salix Pharmaceuticals, Inc. |
Vice President of Finance for North America |
Former |
| Polycom, Inc. |
Vice President of Finance |
Former |
| Emd Serono, Inc. |
|
Former |
| Polycom, Inc. |
Director |
Former |
| The Catholic University of America |
bachelor of arts degree |
Former |
J. David Boyle II , has served as Senior Vice President and Chief Financial Officer of AVI since August 18, 2008, and as the Company's Secretary since September 29, 2008. In the five years prior to his appointment as the Company's Senior Vice President and Chief Financial Officer, Mr. Boyle worked for both XOMA Ltd., a biopharmaceutical company in the field of therapeutic antibody discovery and development, and Polycom, Inc., a worldwide high technology communications company. Mr. Boyle served as Vice President, Finance and Chief Financial Officer of XOMA Ltd. from July 2005 to August 2008. Prior to his position as Chief Financial Officer, Mr. Boyle served as Vice President, Financial Operations of XOMA Ltd. from January 2005 to July 2005. Mr. Boyle joined XOMA Ltd. in January 2005 from Polycom, Inc. where he served from March 2002 to December 2004, most recently, as Vice President, Finance. Mr. Boyle also brings to the Company extensive global financial leadership experience in the pharmaceutical industry through previous senior leadership positions. Prior to his employment with Polycom, Inc., Mr. Boyle worked for Salix Pharmaceuticals, Ltd. in the US and for Ares Serono Group both in the US and Switzerland. Mr. Boyle holds a Bachelor of Arts degree from Catholic University.
| Organization |
Position |
Status |
| AVI BioPharma, Inc. |
Senior Vice President Finance and CFO |
Current |
| Polycom, Inc. |
Chief Financial Officer |
Former |
| Polycom, Inc. |
Vice President of Finance |
Former |
| The Catholic University of America |
Bachelor of Arts Degree |
Former |
J. David Boyle II , has served as Senior Vice President and Chief Financial Officer of AVI since August 18, 2008, and as the Company's Secretary since September 29, 2008. In the five years prior to his appointment as the Company's Senior Vice President and Chief Financial Officer, Mr. Boyle worked for both XOMA Ltd., a biopharmaceutical company in the field of therapeutic antibody discovery and development, and Polycom, Inc., a worldwide high technology communications company. Mr. Boyle served as Vice President, Finance and Chief Financial Officer of XOMA Ltd. from July 2005 to August 2008. Prior to his position as Chief Financial Officer, Mr. Boyle served as Vice President, Financial Operations of XOMA Ltd. from January 2005 to July 2005. Mr. Boyle joined XOMA Ltd. in January 2005 from Polycom, Inc. where he served from March 2002 to December 2004, most recently, as Vice President, Finance. Mr. Boyle also brings to the Company extensive global financial leadership experience in the pharmaceutical industry through previous senior leadership positions. Prior to his employment with Polycom, Inc., Mr. Boyle worked for Salix Pharmaceuticals, Ltd. in the US and for Ares Serono Group both in the US and Switzerland. Mr. Boyle holds a Bachelor of Arts degree from Catholic University.
| Organization |
Position |
Status |
| AVI BioPharma, Inc. |
Senior Vice President Finance and CFO |
Current |
| Polycom, Inc. |
Chief Financial Officer |
Former |
| Polycom, Inc. |
Vice President of Finance |
Former |
| The Catholic University of America |
Bachelor of Arts Degree |
Former |
Mr. Medeiros joined AVI in May 2009 and brings more than 17 years experience in pharmaceutical and biotechnology business development. He most recently served as Vice President, Global Licensing and Strategic Alliances for Schering-Plough, where he led worldwide specialty product licensing and strategic partnering initiatives. Medeiros joined Schering-Plough in 1996 as marketing planning director, and subsequently held senior positions of increasing responsibility in marketing and business development. Prior to Schering-Plough, Medeiros was employed by Merck & Company, where he held positions in Field Sales, New Product Planning and Worldwide Human Health Marketing. Medeiros holds an A.B. with honors from Brown University and an M.B.A. from Columbia Business School. He is a member of the Licensing Executives Society and the American Marketing Association.
| Organization |
Position |
Status |
| AVI BioPharma, Inc. |
Senior Vice President of Business Development, Chief Business Officer |
Current |
| Schering-Plough Corporation |
Vice President, Global Licensing |
Current |
| Schering-Plough Corporation |
Marketing Planning Director |
Former |
| Brown University |
A.B. With Honors |
Former |
Stephen B. Shrewsbury, M.D. , has served as Chief Medical Officer and Senior Vice President of Preclinical, Clinical and Regulatory Affairs since January 26, 2009. In the five years prior to his appointment as the Company's Chief Medical Officer and Senior Vice President of Preclinical, Clinical and Regulatory Affairs, Dr. Shrewsbury worked as a consultant to the Pharmaceutical Industry (August 2008- January 2009); for Adamas Pharmaceuticals Inc., as Chief Medical Officer & Senior Vice President, Clinical Development, Medical and Regulatory Affairs (from March 2008 to August 2008) a pharmaceutical company in the field of development and commercialization of controlled release products, and MAP Pharmaceuticals Inc., as Chief Medical Officer, Formerly Vice President, Clinical and Regulatory Affairs (from February 2005 to March 2008) a pharmaceutical company, specializing in inhaled delivery of drugs. Prior to his employment with MAP Pharmaceuticals, Inc., Dr. Shrewsbury worked as Senior Director of Clinical Development of Chiron Corporation from July 2002 until February 2005. Prior to joining Chiron, Dr. Shrewsbury held several senior positions at GlaxoSmithKline both in the UK and U.S. from 1993 until 2002. Dr. Shrewsbury holds a Bachelor of Medicine and a Bachelor of Surgery degree from Liverpool, UK.
| Organization |
Position |
Status |
| AVI BioPharma, Inc. |
Chief Medical Officer and Senior Vice President of Clinical and Regulatory Affairs |
Current |
Dwight D. Weller, Ph.D. joined AVI as a director in 1991, serving in that capacity until 2007. He served as Vice President of Chemistry from 1992 to 1997, and has served as Senior Vice President of Chemistry and Manufacturing since 1997. Previously a member of the faculty of Oregon State University since 1978, he was Associate Professor in its Chemistry Department from 1984 to 1992.
Patrick L. Iversen, Ph.D. served as Senior Vice President of Research and Development from 1997 to 2008 (and a director from 1997 to 2007), assuming this new role in 2008. From 1987 through 1997, he was on the staff of the University of Nebraska Medical Center. Dr. Iversen has published extensively on antisense research and development, and has been a consultant to companies including Glaxo Inc., Innovir Pharmaceuticals, Lynx Therapeutics, and Isis Pharmaceuticals.
Prof. Ryszard Kole , Ph.D., is the President and Chairman of Scientific Advisory Board. He is currently a Professor in the Department of Pharmacology and the Lineberger Comprehensive Cancer Center at the University of North Carolina and has been on the faculty of the University since 1983. He was a Visiting Professor at Friedrich Miesher Institute, Ciba-Geigy in Basel, Switzerland (1990). He has published over 80 papers in leading scientific journals and presented his work at numerous national and international meetings. Dr. Kole is on editorial boards of scientific journals, NIH advisory study sections, including Small Business Innovation Research, and a member of the Board of Trustees of the Institute of Biochemistry and Biophysics, Polish Academy of Sciences. He has trained 12 doctoral and 16 post-doctoral students and trainees. Dr. Kole received his M.Sc. degree in Chemistry and Ph.D. degree in Molecular Biology from the University of Warsaw, Poland. His postdoctoral training was at Yale University, including a fellowship at the laboratory of Dr. Sidney Altman, the recipient of the Nobel Prize in RNA maturation. He is a world-class expert in the area of RNA processing and holds several patents for methods of correcting aberrant splicing.
| Organization |
Position |
Status |
| Ercole Biotech, Inc. |
President and Chairman of Scientific Advisory Board |
Current |
| AVI BioPharma, Inc. |
Senior Vice President of Discovery Research |
Current |
| The University of North Carolina |
Professor |
Current |
| Ercole, Inc. |
President |
Former |
| Ercole, Inc. |
Chief Scientific Officer |
Former |
| Ercole Biotech, Inc. |
Senior Vice President of Discovery Research |
Former |
| Ercole, Inc. |
Founder |
Former |
| Ercole Biotech, Inc. |
Scientific Founder |
Former |
| Ercole Biotech, Inc. |
Consultant |
Former |
| The Rna |
|
Former |
| Ercole Biotech, Inc. |
Board of Directors |
Former |
| Organization |
Position |
Status |
| AVI BioPharma, Inc. |
Vice President of Regulatory Affairs and Quality |
Current |
| AVI BioPharma, Inc. |
Senior Director |
Former |
| American Hospital Supply Corporation |
Employee |
Former |
| Organization |
Position |
Status |
| Lippert/Heilshorn & Associates |
Senior Vice President,Principal, Los Angeles Office |
Current |
| Sitrick & Co |
Vice President |
Current |
| AVI BioPharma, Inc. |
Vice President, Lippert, Heilshorn & Associates |
Current |
| Dresner Corporate Services, Inc. |
Vice President |
Former |
| Dresner Corporate Services, Inc. |
Western Region Manager |
Former |
| Sitrick & Co |
Board of Directors |
Former |
| University of Washington |
MA In Communications |
Former |
| University of Washington |
BA |
Former |
| Organization |
Position |
Status |
| AVI BioPharma, Inc. |
Vice President of Business Development |
Current |
| Cummings Consulting LLC |
President |
Former |
| Aradigm Corporation |
Vice President of Business Development |
Former |
| Cummings Consulting LLC |
Founder |
Former |
Shirley Leow joined the Company in August 2008 and brings more than 35 years experience in the biotech and pharmaceutical industry. Prior to joining AVI, Shirley served in key clinical and program management leadership positions in Xanthus Pharmaceuticals, Wyeth, Navigant Biotechnologies and Pharmacia, managing staff and teams toward successful product candidate transitions from early development to global market launch. She also served on an NIH Scientific Steering Committee in the early fight against AIDS and worked extensively with the National Cancer Institute in numerous drug development programs. Shirley recently received the honor of Cambridge Who’s Who Female Executive Leader of the Year for the pharmaceutical industry.
| Organization |
Position |
Status |
| AVI BioPharma, Inc. |
Vice President of Clinical Operations and Project Management |
Current |
| National Cancer Institute |
|
Former |
M. Kathleen Behrens, Ph.D. , has served as a director of AVI since March 31, 2009. Dr. Behrens' career spans the financial services and biotechnology sectors, as well as healthcare policy. Dr. Behrens served as a member of the President's Council of Advisors on Science and Technology (PCAST) from 2001 to early 2009 and she was Chair of PCAST's Subcommittee on Personalized Medicine. She has served as a public-market biotechnology securities analyst as well as venture capitalist focusing on healthcare, technology and related investments. She was instrumental in the founding of several biotechnology companies including Protein Design Labs, Inc. and COR Therapeutics, Inc., and more recently was a Director of Abgenix, Inc., which was acquired by Amgen in 2006. She worked for Robertson Stephens & Co. from 1983 through 1996, serving as a general partner and managing director. Dr. Behrens continued in her capacity as a General Partner for selected venture funds for RS Investments from 1996 through today. From 1997 to 2005, she was a director of the Board on Science, Technology and Economic Policy (STEP) for the National Research Council, and from 1993 to 2000 she was a director, President, Chair and Past Chair of the National Venture Capital Association. Dr. Behrens holds a Ph.D. in Microbiology from the University of California, Davis.
| Organization |
Position |
Status |
| AVI BioPharma, Inc. |
Postdoctoral Fellow In the Laboratory of Dr. |
Current |
| Organization |
Position |
Status |
| AVI BioPharma, Inc. |
Chairman |
Current |
| AVI BioPharma, Inc. |
Director |
Current |
| Celgene Corporation |
Director |
Current |
| American Cyanamid Company |
Executive Vice President |
Former |
| The Johns Hopkins University |
member |
Former |
| NeoRx Corporation |
chairman |
Former |
| Johnson & Johnson |
Group Chairman |
Former |
| Targeted Genetics Corporation |
Board of Directors |
Former |
| Western Washington University |
B.Ed. |
Former |
| Organization |
Position |
Status |
| DURECT Corporation |
Director, Chairman of the Nominating and Governance Committee |
Current |
| Allos Therapeutics, Inc. |
Pharmaceutical Industry Consultant |
Current |
| DURECT Corporation |
Director |
Current |
| Cholestech Corporation |
Director |
Current |
| Lead Discovery |
Board of Directors |
Current |
| AVI BioPharma, Inc. |
Director |
Current |
| Bone Care International, Inc. |
Director |
Current |
| Celgene Corporation |
Board of Directors |
Current |
| Inex Pharmaceuticals Corporation |
Director |
Current |
| Orthologic Corporation |
Director |
Current |
| Allos Therapeutics, Inc. |
Director |
Current |
| Multiple Myeloma |
Committee Member |
Current |
| Pharmion Corporation |
Committee Member |
Current |
| Rare Diseases Clinical Research Network |
Committee Member |
Current |
| Genetic Therapy, Inc. |
President |
Former |
| Genetic Therapy, Inc. |
Chief Operating Officer |
Former |
| Ortho Pharmaceutical Corporation |
Vice President, Sales and Marketing |
Former |
| Johnson & Johnson |
Vice President of Sales and Marketing |
Former |
Professor of Immunology, and President, Karolinska Institute Professor Wigzell has been the President of the Karolinska Institute since 1995. He graduated from the Karolinska Institute as a Physician (MD). He also attained a DSc and took a post as a special cancer scientist with the Swedish Cancer Society. In 1971 he returned to the Karolinska as Acting Associate Professor in the Department of Tumor Biology. After two years he became a Professor in the Department of Immunology at Uppsala University Medical School. In 1982 he returned again to the Karolinska as a Professor in the Department of Immunology and in 1988 he became Director General of the National Bacteriological Laboratory in Stockholm.
| Organization |
Position |
Status |
| Parallel Solutions, Inc |
Advisor and Founder |
Current |
| Affibody Ab Och Inforsense, Ltd. |
Co-Founder |
Current |
| EntreMed, Inc. |
Professor |
Current |
| Karolinska Development |
Chairman of the Board |
Current |
| EntreMed, Inc. |
Board of Directors |
Current |
| Parallel Solutions, Inc |
Board of Directors |
Current |
| Karolinska Investment Fund |
Board of Directors |
Current |
| Affibody Ab Och Inforsense, Ltd. |
Board of Directors |
Current |
| Epiphany Biosciences, Inc. |
Board of Directors |
Current |
| AVI BioPharma, Inc. |
Board of Directors |
Current |
| Karolinska Institute |
President |
Former |
| Karolinska Institute |
Chief Scientific Advisor |
Former |
| Karolinska Institute |
Physician |
Former |
| Uppsala University |
Professor |
Former |
| Karolinska Institute |
M.D. |
Former |
| Organization |
Position |
Status |
| AVI BioPharma, Inc. |
Board of Directors |
Current |
| AVI BioPharma, Inc. |
Chairman, Bmg Pharma Llc |
Former |
| University of California, Santa Barbara |
Bachelor of Arts Degree |
Former |
Executive News
-
AVI BioPharma, Inc. (AVII) Presenting at Rodman & Renshaw Global Investment Conference
BioSpace - 9/03/09 - View Story
-
AVI BioPharma Phase 1 Proof of Concept and Safety Data for
Market Wire via MSN Money - 8/25/09 - View Story
-
AVI BioPharma to Present Safety Data in Duchenne Muscular
Market Wire via MSN Money - 8/25/09 - View Story
-
Biotech Dealmaking Takes a Summer Breather
Seeking Alpha - 8/23/09 - View Story
-
AVI BioPharma, Inc. (AVII) Announces Second Quarter 2009 Financial Results & Corporate Highlights
BioSpace - 8/11/09 - View Story
-
AVI BioPharma Announces Second Quarter 2009 Financial Results &
Market Wire via MSN Money - 8/10/09 - View Story
-
AVI BioPharma Announces Second Quarter 2009 Financial Results & Corporate Highlights
Market Wire - 8/10/09 - View Story